Andreas W. Berger

1.1k total citations
39 papers, 779 citations indexed

About

Andreas W. Berger is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andreas W. Berger has authored 39 papers receiving a total of 779 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 21 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andreas W. Berger's work include Pancreatic and Hepatic Oncology Research (20 papers), Cancer Genomics and Diagnostics (19 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers). Andreas W. Berger is often cited by papers focused on Pancreatic and Hepatic Oncology Research (20 papers), Cancer Genomics and Diagnostics (19 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers). Andreas W. Berger collaborates with scholars based in Germany, Austria and United States. Andreas W. Berger's co-authors include Thomas Seufferlein, Thomas J. Ettrich, Alexander Kleger, Edgars Endzeliņš, Marta Rodríguez, Alicia Llorente, Cristina Bajo-Santos, Daiga Šantare, Artūrs Ābols and V. Lietuvietis and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

In The Last Decade

Andreas W. Berger

33 papers receiving 767 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andreas W. Berger Germany 11 410 342 269 208 197 39 779
Suguru Fukahori Japan 12 35 0.1× 78 0.2× 129 0.5× 97 0.5× 157 0.8× 58 492
Ming‐Hsien Tsai Taiwan 10 48 0.1× 127 0.4× 95 0.4× 98 0.5× 95 0.5× 46 424
Kaitao Yuan China 11 84 0.2× 82 0.2× 104 0.4× 70 0.3× 71 0.4× 20 424
Baoxing Liu China 14 299 0.7× 96 0.3× 388 1.4× 129 0.6× 129 0.7× 51 687
Han Zhu China 12 134 0.3× 76 0.2× 316 1.2× 170 0.8× 68 0.3× 19 618
Shuanglan Xu China 12 109 0.3× 141 0.4× 157 0.6× 179 0.9× 82 0.4× 42 501
Shanhua Mao China 12 150 0.4× 57 0.2× 260 1.0× 93 0.4× 70 0.4× 34 557
Abelardo Meneses‐García Mexico 15 40 0.1× 197 0.6× 174 0.6× 80 0.4× 164 0.8× 34 665
İsmail Gömceli Türkiye 12 253 0.6× 142 0.4× 271 1.0× 57 0.3× 218 1.1× 36 613
Viola Barucca Italy 13 116 0.3× 343 1.0× 90 0.3× 111 0.5× 115 0.6× 19 496

Countries citing papers authored by Andreas W. Berger

Since Specialization
Citations

This map shows the geographic impact of Andreas W. Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas W. Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas W. Berger more than expected).

Fields of papers citing papers by Andreas W. Berger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas W. Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas W. Berger. The network helps show where Andreas W. Berger may publish in the future.

Co-authorship network of co-authors of Andreas W. Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas W. Berger. A scholar is included among the top collaborators of Andreas W. Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas W. Berger. Andreas W. Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Seufferlein, Thomas, Ludwig Lausser, Alexander Stein, et al.. (2024). Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer—Results of the prospective multicenter PERMAD trial. PLoS ONE. 19(6). e0304324–e0304324.
5.
Sappok, Tanja, et al.. (2024). Krebserkrankungen bei Menschen mit einer Intelligenzminderung in Deutschland: Prävalenzen, Genetik und Versorgungslage. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 67(3). 362–369.
6.
Horn, Andreas, Florian Roghmann, Martin Loss, et al.. (2023). Endoscopic trans-anal tube placement is a safe and helpful tool for colonic decompression: final results of a standardized single-centre retrospective assessment of 125 patients. Zeitschrift für Gastroenterologie. 62(2). 175–182. 1 indexed citations
7.
Seufferlein, Thomas, Waldemar Uhl, Hana Algül, et al.. (2021). LBA56 Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study. Annals of Oncology. 32. S1333–S1333. 5 indexed citations
8.
9.
Berger, Andreas W., Anke Reinacher‐Schick, Waldemar Uhl, et al.. (2019). A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Theranostics. 9(5). 1280–1287. 43 indexed citations
10.
Ettrich, Thomas J., Anna Dolnik, Tamara J. Blätte, et al.. (2019). Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information. Scientific Reports. 9(1). 13261–13261. 84 indexed citations
11.
Ettrich, Thomas J., Andreas W. Berger, Thomas Decker, et al.. (2019). Nintedanib versus placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: TRICC-C trial—Final results from the randomized phase II trial of the AIO.. Journal of Clinical Oncology. 37(4_suppl). 666–666. 1 indexed citations
12.
13.
Ettrich, Thomas J., Andreas W. Berger, Thomas Seufferlein, & Lukas Perkhofer. (2018). Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced cholangiocarcinoma: The AIO-NIFE-trial, an open label, randomized, multicenter phase II trial.. Journal of Clinical Oncology. 36(15_suppl). TPS4145–TPS4145. 1 indexed citations
14.
Berger, Andreas W., Thomas J. Ettrich, Anna Dolnik, et al.. (2018). Genotyping of circulating tumor DNA in biliary tract cancer to reveal diagnostic and prognostic information.. Journal of Clinical Oncology. 36(4_suppl). 291–291. 2 indexed citations
15.
Berger, Andreas W., Cord Langner, Leopold Ludwig, et al.. (2017). Genetic Biopsy for Prediction of Surveillance Intervals after Endoscopic Resection of Colonic Polyps: Results of the GENESIS Study. United European Gastroenterology Journal. 6(2). 290–299. 5 indexed citations
16.
Berger, Andreas W., H. G. Welz, Ralf Marienfeld, et al.. (2017). Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA. PLoS ONE. 12(3). e0174308–e0174308. 35 indexed citations
17.
18.
Ettrich, Thomas J., Lukas Perkhofer, Goetz von Wichert, et al.. (2016). DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer. 16(1). 21–21. 15 indexed citations
19.
Ettrich, Thomas J., Andreas W. Berger, Alexander Zipprich, et al.. (2015). 2363 Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (Soradox trial): final results of a prospective, randomized, open-label, multicenter phase IIb trial. European Journal of Cancer. 51. S457–S457. 1 indexed citations
20.
Amann, W., Andreas W. Berger, W. Schweiger, et al.. (1997). Percutaneous endoscopic gastrostomy (PEG) 8 years of clinical experience in 232 patients. Surgical Endoscopy. 11(7). 741–744. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suguru Fukahori Breakdown of academic impact, for papers by Ming‐Hsien Tsai Breakdown of academic impact, for papers by Kaitao Yuan Breakdown of academic impact, for papers by Baoxing Liu Breakdown of academic impact, for papers by Han Zhu Breakdown of academic impact, for papers by Shuanglan Xu Breakdown of academic impact, for papers by Shanhua Mao Breakdown of academic impact, for papers by Abelardo Meneses‐García Breakdown of academic impact, for papers by İsmail Gömceli Breakdown of academic impact, for papers by Viola Barucca
Rankless by CCL
2026